Owkin has signed a three-year licensing agreement with AstraZeneca to develop biopharma AI agents on its K Pro platform, integrating multimodal data and agentic AI into AstraZeneca’s decision workflows for competitive intelligence, reducing manual analysis.
Owkin, an agentic AI company focused on biological artificial superintelligence for drug discovery, has announced an agreement with AstraZeneca to build biopharma agents as part of a three-year licensing of K Pro, Owkin’s AI scientist for biopharma decision-making, according to official disclosures. Under the agreement, Owkin will lead end-to-end development of AI agents integrated within AstraZeneca’s IT infrastructure and decision workflows. The agents are designed to help AstraZeneca teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis while maintaining governance, security, and enterprise standards.
This development matters because the pharmaceutical industry is increasingly adopting agentic AI to accelerate decision-making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. The agreement builds on previous collaboration between the two companies to develop an AI gBRCA pre-screen solution for breast cancer, which demonstrated potential to rule out approximately 40% of patients unlikely to carry gBRCA mutations with 93% sensitivity (published at ESMO). That work now continues at Waiv, Owkin’s diagnostic division spin-out, while Owkin focuses on its core aim of developing biological artificial superintelligence for complex biology. Industries impacted include drug discovery, AI-driven biopharma analytics, and competitive intelligence.
Stakeholders include pharmaceutical R&D teams, clinical researchers, and enterprise IT security functions.
For investors, this licensing agreement signals growing enterprise adoption of specialized agentic AI platforms in pharma, with recurring revenue potential for Owkin. Success will depend on seamless integration into AstraZeneca’s workflows and demonstrated ROI in decision speed and accuracy.
Owkin is an AI biotechnology company headquartered in Paris and New York, focusing on multimodal data and agentic AI for drug development.
AstraZeneca is a global pharmaceutical company based in Cambridge, UK, engaged in oncology, cardiovascular, and respiratory drug discovery.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.